Literature DB >> 10566152

Mucosal immunity and tolerance: relevance to vaccine development.

C Czerkinsky1, F Anjuere, J R McGhee, A George-Chandy, J Holmgren, M P Kieny, K Fujiyashi, J F Mestecky, V Pierrefite-Carle, C Rask, J B Sun.   

Abstract

The mucosal immune system of mammals consists of an integrated network of lymphoid cells which work in concert with innate host factors to promote host defense. Major mucosal effector immune mechanisms include secretory antibodies, largely of immunoglobulin A (IgA) isotype, cytotoxic T cells, as well as cytokines, chemokines and their receptors. Immunologic unresponsiveness (tolerance) is a key feature of the mucosal immune system, and deliberate vaccination or natural immunization by a mucosal route can effectively induce immune suppression. The diverse compartments located in the aerodigestive and genitourinary tracts and exocrine glands communicate via preferential homing of lymphocytes and antigen-presenting cells. Mucosal administration of antigens may result in the concomitant expression of secretory immunoglobulin A (S-IgA) antibody responses in various mucosal tissues and secretions, and under certain conditions, in the suppression of immune responses. Thus, developing formulations based on efficient delivery of selected antigens/tolerogens, cytokines and adjuvants may impact on the design of future vaccines and of specific immunotherapeutic approaches against diseases associated with untoward immune responses, such as autoimmune disorders, allergic reactions, and tissue-damaging inflammatory reactions triggered by persistent microorganisms.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10566152      PMCID: PMC7165636          DOI: 10.1111/j.1600-065x.1999.tb01339.x

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  253 in total

Review 1.  Is BALT a major component of the human lung immune system?

Authors:  R Pabst
Journal:  Immunol Today       Date:  1992-04

2.  Specific immune induction following DNA-based immunization through in vivo transfection and activation of macrophages/antigen-presenting cells.

Authors:  M A Chattergoon; T M Robinson; J D Boyer; D B Weiner
Journal:  J Immunol       Date:  1998-06-15       Impact factor: 5.422

3.  Lymphoid and non-lymphoid cells in nasal-associated lymphoid tissue (NALT) in the rat. An immuno- and enzyme-histochemical study.

Authors:  C F Kuper; D M Hameleers; J P Bruijntjes; I van der Ven; J Biewenga; T Sminia
Journal:  Cell Tissue Res       Date:  1990-02       Impact factor: 5.249

4.  Leukocytes in the intestinal epithelium: an unusual immunological compartment.

Authors:  P B Ernst; A Dean Befus; J Bienenstock
Journal:  Immunol Today       Date:  1985-02

5.  A mouse T cell product that preferentially enhances IgA production. I. Biologic characterization.

Authors:  R L Coffman; B Shrader; J Carty; T R Mosmann; M W Bond
Journal:  J Immunol       Date:  1987-12-01       Impact factor: 5.422

Review 6.  Cholera toxin B subunit as transmucosal carrier-delivery and immunomodulating system for induction of antiinfectious and antipathological immunity.

Authors:  C Czerkinsky; J B Sun; M Lebens; B L Li; C Rask; M Lindblad; J Holmgren
Journal:  Ann N Y Acad Sci       Date:  1996-02-13       Impact factor: 5.691

7.  Mucosal vaccination with recombinant poxvirus vaccines protects ferrets against symptomatic CDV infection.

Authors:  J Welter; J Taylor; J Tartaglia; E Paoletti; C B Stephensen
Journal:  Vaccine       Date:  1999-01-28       Impact factor: 3.641

8.  Secretory immunity in the female reproductive tract.

Authors:  W H Kutteh; J Mestecky
Journal:  Am J Reprod Immunol       Date:  1994-01       Impact factor: 3.886

9.  A plant-based cholera toxin B subunit-insulin fusion protein protects against the development of autoimmune diabetes.

Authors:  T Arakawa; J Yu; D K Chong; J Hough; P C Engen; W H Langridge
Journal:  Nat Biotechnol       Date:  1998-10       Impact factor: 54.908

10.  Transforming growth factor-beta 1 is a costimulator for IgA production.

Authors:  P H Kim; M F Kagnoff
Journal:  J Immunol       Date:  1990-05-01       Impact factor: 5.422

View more
  55 in total

1.  Type 1 immunity provides optimal protection against both mucosal and systemic Trypanosoma cruzi challenges.

Authors:  D F Hoft; C S Eickhoff
Journal:  Infect Immun       Date:  2002-12       Impact factor: 3.441

2.  Home sweet home: How do virus specific T cells navigate to the skin?

Authors:  Anthony L Cunningham
Journal:  J Clin Invest       Date:  2002-08       Impact factor: 14.808

Review 3.  Evaluation of events occurring at mucosal surfaces: techniques used to collect and analyze mucosal secretions and cells.

Authors:  Bruno Guy
Journal:  Clin Diagn Lab Immunol       Date:  2002-07

Review 4.  Mucosal immunity: overcoming the barrier for induction of proximal responses.

Authors:  Brent S McKenzie; Jamie L Brady; Andrew M Lew
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

5.  An HIV-1 tat-autoantigen fusion protein suppresses insulitis in NOD mice.

Authors:  Tae-Geum Kim; Jie Yu; John Hough; David Henderson; William H R Langridge
Journal:  Mol Biotechnol       Date:  2005-07       Impact factor: 2.695

Review 6.  Anticandidal immunity and vaginitis: novel opportunities for immune intervention.

Authors:  Antonio Cassone; Flavia De Bernardis; Giorgio Santoni
Journal:  Infect Immun       Date:  2007-06-11       Impact factor: 3.441

7.  Rice-based mucosal vaccine as a global strategy for cold-chain- and needle-free vaccination.

Authors:  Tomonori Nochi; Hidenori Takagi; Yoshikazu Yuki; Lijun Yang; Takehiro Masumura; Mio Mejima; Ushio Nakanishi; Akiko Matsumura; Akihiro Uozumi; Takachika Hiroi; Shigeto Morita; Kunisuke Tanaka; Fumio Takaiwa; Hiroshi Kiyono
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-15       Impact factor: 11.205

8.  TLR4 and TLR21 expression, MIF, IFN-β, MD-2, CD14 activation, and sIgA production in chickens administered with EFAL41 strain challenged with Campylobacter jejuni.

Authors:  Karaffová V; Marcinková E; Bobíková K; Herich R; Revajová V; Stašová D; Kavuľová A; Levkutová M; Levkut M; Lauková A; Ševčíková Z; Levkut M
Journal:  Folia Microbiol (Praha)       Date:  2016-10-03       Impact factor: 2.099

9.  Kinetics of local and systemic immune responses after vaginal immunization with recombinant cholera toxin B subunit in humans.

Authors:  Lotta Wassen; Marianne Jertborn
Journal:  Clin Diagn Lab Immunol       Date:  2005-03

10.  Pathophysiological significance of a reaction in mouse gastrointestinal tract associated with delayed-type hypersensitivity.

Authors:  Wan-Gui Yu; Ping Lin; Hui Pan; Lan Xiao; En-Cong Gong; Lin Mei
Journal:  World J Gastroenterol       Date:  2004-08-01       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.